Trump's Bold Pharmaceutical Tariff Plan: Impact on Drug Pricing Deals

President Donald Trump has signed an executive order imposing a 100% tariff on imported branded pharmaceuticals not made domestically unless manufacturers align with government drug pricing policies. While large companies have deals in place that exempt them from tariffs, small and mid-sized businesses face penalties unless they relocate production or negotiate new agreements.

President Donald Trump enacted a significant executive order on Thursday, imposing steep 100% tariffs on branded pharmaceuticals not produced in the United States. This measure aims to urge pharmaceutical giants to agree either to U.S. government pricing deals or to manufacture their products domestically.

Many of the world's leading drug manufacturers have already signed agreements with the U.S. government, exempting billions of dollars in drugs from these tariffs. However, smaller and mid-sized pharmaceutical companies face potential penalties unless they secure separate arrangements or move their production facilities stateside.

The executive order grants large pharmaceutical companies 120 days to unveil plans to skirt the tariffs, while smaller enterprises have a 180-day window. Manufacturers that choose to relocate to the U.S. receive a significant tariff reduction. This move is part of a broader strategy to align U.S. drug prices with those of other high-income countries.

(With inputs from agencies.)